Alliance Pharma PLC Director Dealing (6659G)

TIDMAPH

RNS Number : 6659G

Alliance Pharma PLC

20 July 2023

 
 20 July 2023 
 

ALLIANCE PHARMA PLC

("Alliance" or the " Company ")

Director Dealing

Alliance Pharma plc (AIM: APH), the international healthcare group , has been notified that Jo LeCouilliard, the non-executive Chair of the Company, purchased 40,957 ordinary shares of 1.0p each in the Company ("Ordinary Shares") at a price of 48.8 pence per share on 20(th) July 2023.

Following this transaction, (i) Jo LeCouilliard's total beneficial interest in the Company is 40,957 Ordinary Shares, representing 0.008% of the Company's issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 
 1     Details of the person discharging managerial responsibilities/person 
        closely associated 
 a)    Name                                    Jo LeCouilliard 
      --------------------------------------  --------------------------------------------------- 
 2     Reason for the notification 
      ------------------------------------------------------------------------------------------- 
 a)    Position/status                         Non-executive Chair, PDMR 
      --------------------------------------  --------------------------------------------------- 
 b)    Initial notification                    Initial Notification 
        /Amendment 
      --------------------------------------  --------------------------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ------------------------------------------------------------------------------------------- 
 a)    Name                                    Alliance Pharma Plc 
      --------------------------------------  --------------------------------------------------- 
 b)    Legal Entity                            213800RYIWZA4Q5WPZ13 
        Identifier 
      --------------------------------------  --------------------------------------------------- 
 4     Details of the transaction(s): section to be repeated 
        for (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      ------------------------------------------------------------------------------------------- 
 a)    Description                             Ordinary shares of 1 pence each 
        of the financial 
        instrument, 
        type of instrument 
 
        Identification 
        code                                    GB0031030819 
      --------------------------------------  --------------------------------------------------- 
 b)    Nature of                               Purchase of shares 
        the transaction 
      --------------------------------------  --------------------------------------------------- 
 c)    Currency                                GBP 
      --------------------------------------  --------------------------------------------------- 
 d)    Price(s)                                       Price(s)                  Volume(s) 
        and volume(s) 
      --------------------------------------  -----------------------  -------------------------- 
                                                        48.8                     40,957 
 -------------------------------------------  -----------------------  -------------------------- 
 
 e)    Aggregated 
        information                              40,957 Ordinary Shares, bought at a price of 
        - Aggregated                             48.8 pence per share, totalling GBP 19,987.02. 
        volume 
        - Price 
        - Aggregated 
        total 
      --------------------------------------  --------------------------------------------------- 
 f)    Date of the                             20 July 2023 
        transaction 
      --------------------------------------  --------------------------------------------------- 
 g)    Place of                                London Stock Exchange, AIM 
        the transaction 
      --------------------------------------  --------------------------------------------------- 
 

For further information:

 
 Alliance Pharma plc                             + 44 (0)1249 466966 
 Cora McCallum, Head of Investor Relations 
  & Corporate Communications                     + 44 (0)1249 705168 
 [e-mail] 
 
 Buchanan                                       + 44 (0)20 7466 5000 
 Mark Court / Hannah Ratcliff 
 [e-mail] 
 
 Numis Securities Limited (Nominated Adviser 
  and Joint Broker)                             + 44 (0)20 7260 1000 
 Freddie Barnfield / Duncan Monteith / Sher 
  Shah 
 
 Investec Bank plc (Joint Broker)               + 44 (0)20 7597 5970 
 Patrick Robb / Maria Gomez de Olea 
 

About Alliance

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.

We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.

Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands.

For more information on Alliance, please visit our website : www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHVBLBLXDLEBBL

(END) Dow Jones Newswires

July 20, 2023 04:54 ET (08:54 GMT)